Circulating Angiogenic Factors Associated with Response and Survival in Patients with Acute Graft-versus-Host Disease: Results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802  by Holtan, Shernan G. et al.
Biol Blood Marrow Transplant 21 (2015) 1029e1036Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgCirculating Angiogenic Factors Associated with Response
and Survival in Patients with Acute Graft-versus-Host Disease:
Results from Blood and Marrow Transplant Clinical Trials
Network 0302 and 0802Shernan G. Holtan 1,*, Michael R. Verneris 1, Kirk R. Schultz 2,3, Laura F. Newell 4,
Gabrielle Meyers 4, Fiona He 5, Todd E. DeFor 1, Gregory M. Vercellotti 1, Arne Slungaard 1,
Margaret L. MacMillan 1, Sarah A. Cooley 1, Bruce R. Blazar 1, Angela Panoskaltsis-Mortari 1,
Daniel J. Weisdorf 1,3
1Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
2Division of Pediatric Hematology/Oncology/BMT, BC Children’s Hospital, Vancouver, University of British Columbia
3Blood and Marrow Transplant Clinical Trials Network, Rockville, Maryland
4Blood and Marrow Transplant Program, Oregon Health & Science University, Portland, Oregon
5 School of Medicine, University of Minnesota, Minneapolis, MinnesotaArticle history:
Received 20 January 2015
Accepted 17 February 2015
Key Words:
Allogeneic hematopoietic cell
transplantation
Acute graft-versus-host disease
Angiogenic factor
Epidermal growth factor
Vascular endothelial growth
factor
Placental growth factor
FollistatinFinancial disclosure: See Acknowle
* Correspondence and reprint re
Professor of Medicine, Blood and M
Minnesota, 420 Delaware Street SE
E-mail address: sgholtan@umn
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2015 American Sociea b s t r a c t
Circulating angiogenic factors (AF) reﬂect tissue healing capacity, although some AF can also contribute to
inﬂammation and are indicative of endothelial dysfunction. The AF milieu in acute graft-versus-host disease
(aGVHD) has not been broadly characterized. We hypothesized that patients with abundant AF involved in
repair/regeneration versus those mediating damage/inﬂammation would have improved outcomes. Circu-
lating AF known predominantly for repair/regeneration (epidermal growth factor [EGF], ﬁbroblast growth
factor-1 and -2, heparin bindingeEGFelike growth factor, and vascular endothelial growth factor-A [VEGF-A],
-C, and -D) and for damage/inﬂammation (angiopoietin-2, endothelin-1, soluble endoglin [sEng], follistatin
[FS], leptin, and placental growth factor [PlGF]) were measured in a discovery set of hematopoietic cell re-
cipients with grade III and IV aGVHD and compared with controls, then validated in 2 aGVHD cohorts enrolled
in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trials 0302 (n ¼ 105, serum) and 0802
(n ¼ 158, plasma) versus controls without aGVHD (n ¼ 53, serum). Levels of EGF and VEGF-A were lower than
in controls at the onset of aGVHD in both trials and higher with complete response to ﬁrst-line aGVHD
therapy in CTN 0802. FS and PlGF were elevated in aGVHD measured in either serum or plasma. At day 28
after initial aGVHD therapy, elevated FS was an independent negative prognostic factor for survival in both
cohorts (hazard ratio, 9.3 in CTN 0302; 2.8 in CTN 0802). These data suggest that circulating AF are associated
with clinical outcomes after aGVHD and, thus, may contribute to both pathogenesis and recovery.
 2015 American Society for Blood and Marrow Transplantation.BACKGROUND
In the United States, nearly 7000 patients undergo alloge-
neic hematopoietic cell transplantation (HCT) annually in an
effort to cure hematologic malignancies and other bone
marrow disorders. Approximately 50% of these patients will
experience acute graft-versus-host disease (aGVHD), adgments on page 1035.
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ty for Blood and Marrow Transplantation.complication inwhichcells fromthe immunocompetentdonor
graft attack the recipient’s organs and tissues [1]. Only one half
of aGVHD patients achieve a durable response to ﬁrst-line
therapy with corticosteroids [2] and many others develop se-
vere infections resulting from the immunocompromised state
and impairment of skin and mucosal barrier integrity. As a
result, many patientswith severe aGVHD are at signiﬁcant risk
of death [3]. Identiﬁcation of novel treatment approaches that
can alleviate inﬂammation, spare infectious immunity, and
promote healing is critical for improving patient outcomes.
A host vascular proliferative response accompanying
aGVHD was ﬁrst described by Brent and Medawar in the
S.G. Holtan et al. / Biol Blood Marrow Transplant 21 (2015) 1029e103610301960s [4], although it was not clear whether the angiogenic
response in aGVHD could improve outcomes by facilitating
healing or if it was detrimental to outcomes by contributing
to inﬂammation. Recently, mechanisms underlying this
critical observation have been suggested using rodent
models. Speciﬁcally, vasculogenesis accompanies aGVHD
with a concomitant increase in alpha-v integrin expression
on endothelial cells in tissues targeted by aGVHD, a patho-
logic reaction that can be inhibited by a negative regulator of
neovascularization, micro RNA-100, and by the alpha-v
integrin inhibitor cilengitide [5,6]. Despite these advances,
tools to therapeutically target neovascularization in human
aGVHD are lacking. Recent literature suggests that angio-
genic factors (AF), soluble mediators that support the
development of new blood vessels, may contribute to
favorable outcomes by providing trophic factors for wound
healing after injury. This principle has been demonstrated in
the autoimmune inﬂammatory bowel disease (IBD) setting
with epidermal growth factor (EGF), an epithelial and
endothelial mitogen that enhances angiogenic responses in
tissues [7,8]. In IBD, circulating EGF levels have been shown
to be low [9], and supplementation has induced remission in
a randomized trial [10].
Studies of such AF capable of repairing host tissues and
their associations with aGVHD outcomes are emerging. Pa-
tients with single nucleotide polymorphisms associated with
increased production of vascular endothelial growth factor
(VEGF) have a reduced incidence of grade II to IV aGVHD,
including gastrointestinal aGVHD [11]. In addition, single
nucleotide polymorphisms within the gene encoding
thrombomodulin, a constitutively expressed endothelial
factor that enhances angiogenesis [12], are associated with
survival after onset of aGVHD [13]. These genetic studies
suggest that variations in the patient’s capacity to repair
tissues after both the damage from the conditioning regimen
and at the onset of aGVHD are clinically relevant. However,
not all reports have consistently shown a beneﬁcial role for
AF in aGVHD. High circulating levels of VEGF have been
shown to be protective in some aGVHD studies [14,15] but
not in others [16,17]. It is possible that other factors
contributing to the angiogenic milieu may be responsible for
the discrepant results. For example, angiopoietin-2 (Ang2) is
an AF that can have either proangiogenic or antiangiogenic
function, depending upon the context [18]. In allogeneic HCT,
elevated levels of Ang2 are reported to reﬂect endothelial cell
activation/dysfunction and are associated with a poor prog-
nosis in aGVHD [17,19,20].
Given these disparate associations of AF with outcomes in
aGVHD, we sought to more broadly characterize the angio-
genic milieu in aGVHD and determine the association of in-
dividual factors with clinical outcomes. Furthermore, we
compared serum versus plasma levels of AF, because of the
potential for variability contributed by factor release by
activated platelets, a nontrivial matter for future studies of
AF in human disease. Thirteen AF were ﬁrst tested in a pilot
study, followed by the validation of 6 AF using samples from
2 multicenter aGVHD treatment trials, Blood and Marrow
Transplant Clinical Trials Network (BMT CTN) 0302 [21], a
randomized 4-arm phase II clinical trial for patients with
newly diagnosed aGVHD where serum was collected, and
BMT CTN 0802 [22], a randomized phase III study of the
addition of mycophenolate mofetil versus placebo to corti-
costeroids in patients with newly diagnosed aGVHD, where
plasmawas collected. Overall, we hypothesized that patients
with abundant circulating AF involved in repair/regenerationwould have improved outcomes compared with those with
higher levels of AF involved in damage/inﬂammation.
PATIENTS AND METHODS
Discovery Cohort
We measured circulating levels of EGF, ﬁbroblast growth factor (FGF)-1,
FGF-2, heparin bindingeEGFelike growth factor, VEGF-A, -C, and -D, Ang2,
endothelin-1, endoglin (sEng), follistatin (FS), leptin, and placental growth
factor (PlGF) in HCT recipients at onset of grade III and IV aGVHD (patient
discovery set, n¼ 17) and compared themwith recipients without aGVHD at
3 months after HCT (n ¼ 17) and healthy stem cell donors (n ¼ 16). There-
fore, samples from both HCT patients without aGVHD and healthy donors
were tested as controls. Samples were analyzed by MILLIPLEX (Millipore,
Billerica, MA) magnetic bead array and performed in duplicate. For the pilot
study, plasma samples were collected in sodium heparin tubes, except for 13
of the aGVHD specimens, which were serum. The mean coefﬁcient of vari-
ation for the analytes ranged from 1.9% to 7.5%.
Validation Cohorts
AF demonstrating statistically signiﬁcant <.5-fold or >1.5-fold differ-
ences from controls in the pilot study were selected for validation in sam-
ples from 2 multicenter treatment trials for initial therapy of aGVHD: BMT
CTN 0302 (n ¼ 105) and BMT CTN 0802 (n ¼ 158). Serum (0302) or plasma
(0802) samples obtained at aGVHD onset and at day 28 after GVHD treat-
ment were selected for study. All patients with available aGVHD onset and
day 28 post-aGVHD therapy samples were included in this study. Samples
from aGVHD onset in these 2 trials were further compared with serum
samples from a control cohort of HCT patients without acute or chronic
GVHD (n ¼ 53). These control samples were collected 3 months after HCT in
University of Minnesota allogeneic HCT recipients, a time point consistent
with the pilot study. Samples were acquired after obtaining informed con-
sent and approval from the University of Minnesota institutional review
board and in accordance with the Declaration of Helsinki.
Statistical Analysis
Statistical comparisons across categorical variables were completed
using chi-square tests. Differences in continuous variables across categories
were completed using Kruskal-Wallis tests for nonparametric data [23].
Differences between AF levels in onset and day 28 samples were determined
usingWilcoxon signed rank tests [24]. Kaplan-Meier estimates were used to
determine the probability of 2-year survival, with differences between
curves determined using log-rank tests [25]. Cox regression was used to
determine the independent effects of clinical factors and angiogenic bio-
markers on 6-month and overall survival [26]. Correlations between
continuous variables were determined by Spearman’s rank correlation [27].
Receiver operating characteristic (ROC) curves were generated to determine
the value of the tested AF in discriminating aGVHD from no aGVHD. Sta-
tistical analyses were performed using JMP 10.0.0 (SAS Institute, Cary, NC).
RESULTS
Discovery Set
In the discovery cohort, levels of multiple AF differed at
aGVHD onset compared with levels for controls (Figure 1).
Speciﬁcally, among the repair and regeneration factors, the
median EGF level was 10-fold lower in aGVHD patients
compared with those of allogeneic HCT patients without
aGVHD. Similar to EGF, the median VEGF-A level was 5-fold
lower in patients with aGVHD compared with that of con-
trol allogeneic HCT patients and 1.5-fold higher than normal
donors (overall P value of .07). Based on these data and its
importance in angiogenesis, VEGF-A was retained for vali-
dation studies. Four AF associated with damage/inﬂamma-
tionwere signiﬁcantly elevated in aGVHD patients compared
with the levels in healthy donors: Ang2, sEng, FS, and PlGF.
Too few patients had detectable levels of endothelin-1, FGF-1,
and FGF-2 for statistical comparison (not shown). Using the
pilot study data, 6 AF were selected for validation: FS, EGF,
VEGF-A, Ang2, sEng, and PlGF.
Validation Cohorts
Characteristics of the patients in the validation cohorts
are detailed in Table 1. The median age was 6 to 8 years
Figure 1. Discovery set. All results are pg/mL. *Denotes controls versus aGVHD.
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52 years, P ¼ .01), and consequently more patients in the
control cohort underwent reduced-intensity conditioning as
opposed to myeloablative HCT. Patients in the control cohort
had a higher proportion with umbilical cord blood as the
stem cell source (P < .001), reﬂecting institutional practices
in unrelated donor HCT. The majority of patients in the BMT
CTN trials had mild (grade I and II) aGVHD. There was no
difference in the proportion of clinical responses (complete
plus partial responses) to ﬁrst-line therapy at day 28 be-
tween the 2 BMT CTN studies (70.5% and 74.7%, P ¼ .19).
Levels of 5 of the 6 AF studied showed signiﬁcant differ-
ences at onset of aGVHD compared with levels of controlTable 1
Patient Characteristics
Variable BMT CTN 0302 BM
(n ¼ 105) % (n
Age, median (range) 50.3 (7.5-69.9) 52.
Donor type
MSD 42 40.0 50
Matched URD 37 35.2 84
Mismatched URD 2 1.9 2
Other related 7 6.7 11
UCB 16 15.2 2
Missing 1 1.0 9
Conditioning
MA 66 62.9 97
RIC 38 36.2 52
Missing 1 1.0 9
Days to aGVHD, median (range) 33 (13-146) 34
Initial GVHD grade
I 12 11.4 20
II 64 61.0 90
III 26 24.8 29
IV 2 1.9 5
Missing 1 1.0 14
Day 28 response
CR 54 51.4 76
PR 20 19.0 42
NR 29 27.6 31
Missing 2 1.9 9
Allo HCT indicates allogeneic hematopoietic cell transplantation; MSD, matched s
loablative; RIC, reduced-intensity conditioning; N/A, not applicable.recipients without aGVHD (Figure 2, Supplemental Table S1).
Initially, we compared serum levels (from CTN 0302) and
plasma (from CTN 0802) AF to serum controls. VEGF-A and
EGF were signiﬁcantly lower in patients with aGVHD than
they were in controls, similar to ﬁndings in the pilot study.
Additionally, plasma levels of these factors were even lower
than the serum levels. The serum levels of VEGF-A in CTN
0302 were not statistically different than in controls,
whereas EGF levels were signiﬁcantly lower in both serum
and plasma from aGVHD patients. Ang2 serum or plasma
levels were similar to those in controls. Levels of both serum
and plasma FS and PlGF were signiﬁcantly elevated in pa-
tients with onset aGVHD compared with those in controlT CTN 0802 Control Allo HCT P Value
¼ 158) % (n ¼ 53) %
4 (9.1-76.3) 58 (19-72) .01
<.001
31.6 32 60.4
53.2 1 1.9
1.3 0 0.0
7.0 0 0.0
1.3 20 37.7
5.7 0 0.0
<.001
61.4 13 24.5
32.9 40 75.5
5.7 0 0.0
(11-165) N/A .90
N/A .48
12.7
57.0
18.4
3.2
8.9
N/A .19
48.1
26.6
19.6
5.7
ibling donors; URD, unrelated donor; UCB, umbilical cord blood; MA, mye-
Figure 2. Circulating AF at onset of aGVHD in 2 aGVHD treatment trials versus
allogeneic HCT controls.
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plasma. Plasma endoglin levels (from CTN 0802) were
signiﬁcantly elevated over control serum. This was not seen
in aGVHD serum (from CTN 0302).
ROC analyses of data pooled from BMT CTN 0302 and
0802 revealed that 4 of the 6 AF levels could discriminate
aGVHD presence versus its absence: EGF, VEGF-A, FS, and
sEng (Figure 3). The highest sensitivity was observed with
EGF at a level of 70.9 pg/mL, demonstrating a sensitivity of
80%, albeit with a lower speciﬁcity at 35%, and an area underFigure 3. Receiver operating characteristic (ROC) curves for 6 AFthe curve (AUC) of .76 (P ¼ .03). sEng at a level of 1,485.7 pg/
mL had the highest discrimination with, a sensitivity of 42%,
a high speciﬁcity of 89%, with an AUC of .63 (P ¼ .002). ROC
curves generated using only serum samples from CTN 0302
versus serum controls, only VEGF-A, with an AUC of .6 (P ¼
.046) could discriminate between aGVHD and controls
without GVHD. In non-GVHD controls, donor type did in-
ﬂuence AF levels (not shown). Reduced-intensity condition-
ing was associated with lower Ang2 levels than
myeloablative conditioning (median, 3407 pg/mL versus
5235 pg/mL, P ¼ .038). No other clinical variables were
associated with AF levels in controls and thus did not inﬂu-
ence the ROC analysis.
Association of AF with Patient and Donor Factors
AF levels were not associated with time to aGVHD
onset, severity, or organ tropism consistently in either
aGVHD trial (Supplemental Tables S2-S4). EGF levels were
signiﬁcantly lower in recipients of myeloablative condi-
tioning compared with recipients of reduced-intensity
conditioning in CTN 0302 (38 versus 89 pg/mL, P ¼ .005)
but not in CTN 0802 (P ¼ .40). In CTN 0802, recipient age
was associated with a trend toward higher onset FS levels
(P ¼ .07) as well as a trend toward lower day 28 EGF levels
(P ¼ .06). PlGF levels were 1.5-fold higher at the onset of
aGVHD in unrelated donors compared with in HLA-
matched siblings in both trials (CTN 0302, P ¼ .03; CTN
0802, P ¼ .007). No other clinical factors were associated
with levels of these 6 AF at onset or day 28 after initial
therapy for aGVHD.discriminating between the presence or absence of aGVHD.
Figure 4. Association of circulating EGF and VEGF-A at onset of aGVHD and at day 28 after initial aGVHD therapy and clinical response. *Denotes P < .05 compared to
complete response. **Denotes P < .05 day 28 sample compared to the sample from the onset of aGVHD.
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Therapy
In CTN 0802 plasma samples, response to aGVHD therapy
was associated with signiﬁcant differences in circulating
levels of EGF and VEGF-A at day 28 post-initial aGVHD
therapy. EGF levels were 2-fold higher in patients with a
complete response (CR, 20 pg/mL, versus 11 pg/mL for pa-
tients with partial response [PR] and 8 pg/mL for no response
[NR], P ¼ .03) (Figure 4). In addition, EGF levels signiﬁcantly
decreased from the onset of aGVHD to day 28 of therapy in
patients who had NR (P ¼ .01). Similarly for VEGF-A, patients
with a CR had 2-fold higher levels at day 28 (CR, 163 pg/mL
versus 79 pg/mL for PR and 86 pg/mL for NR, P ¼ .008). In
patients with CR to therapy, VEGF-A levels signiﬁcantly
increased from the onset of aGVHD to day 28 of therapy (P ¼
.006). In contrast, in CTN 0302 serum samples, we observed
no differences in EGF levels with response (CR, 46 pg/mL and
PR, 62 pg/mL versus NR, 63 pg/mL, P¼ .20) nor VEGF-A levels
(CR, 215 pg/mL and PR, 195 pg/mL versus NR, 166 pg/mL, P ¼
.80). Importantly, the 0302 samples were serum (not
plasma), which generally is associated with higher levels of
these markers because of release from platelets [28,29].
Additionally, levels of Ang2 and sEng signiﬁcantly
decreased in patients experiencing a CR or PR at day 28 (P <
.001 for each) across both cohorts. However, levels of Ang2
and sEng did not decrease (P ¼ .20 and P ¼ .10, respectively)
in patients with NR at day 28 (Supplemental Figure 1).Association of AF with 6-Month Survival
In CTN 0302 univariate survival analyses, elevated levels
of sEng (P ¼ .04) and Ang2 at aGVHD onset (P ¼ .02) and at
day 28 after initial aGVHD therapy (P¼ .003) were associated
with lower 6-month survival. In CTN 0802, elevated FS (P ¼
.006) and PlGF (P ¼ .006) levels at day 28 after aGVHD
therapy were associated with lower 6-month survival. These
factorsdAng2, sEng, FS, and PlGFdwere tested, along withestablished important clinical variables for outcomes after
allogeneic HCT, including patient age, aGVHD grade, and day
28 response to initial therapy [30], in a multivariate analysis
of 6-month survival. In both trials, day 28 FS was an inde-
pendent factor for 6-month survival (Table 2). The day 28 FS
level of >2000 pg/mL showed the strongest association with
poor survival (Figure 5). In CTN 0302, 80% of patients with a
FS level below the cutoff were alive at 6months versus 20% of
patients with FS above the cutoff (P¼ .001). In CTN 0802, 83%
of patients with a FS below the cutoff were alive at 6 months
versus 58%with a FS above the cutoff (P¼ .02). In the controls
without aGVHD, PlGF at day þ100 was the only AF variable
associated with survival, with poorer survival when the day
100 PlGF level was >40 pg/mL (relative risk, 49.5; 95% con-
ﬁdence interval, 2.0 to 1250; P ¼ .02).DISCUSSION
Without adequate levels of important trophic AF, host
tissues may have compromised healing in the wake of severe
aGVHD. Our study is the ﬁrst to identify markedly low EGF
levels at the onset of aGVHD. Low circulating EGF levels have
been identiﬁed in IBD [9], which has similarities in presen-
tation and perhaps pathogenesis with aGVHD [31]. Our re-
sults provide a rationale for supplementation of deﬁcient
factors to aid in repair as an adjunct to immunosuppression.
The utility of AF replacement has been demonstrated with
the use of EGF-containing enemas in left-sided ulcerative
colitis [10]. The widespread tissue damage associated with
aGVHD suggests that systemic administration of such factors
may be needed. During steady state, the predominant
luminal sources of EGF in the gastrointestinal tract are sali-
vary and Brunner’s glands, although Paneth cells, a known
target of GVHD, have also been identiﬁed as producers of EGF
[32,33]. We hypothesize that the low EGF levels we observed
in GVHD are related to an alloimmune attack on EGF-
producing cells, although increased EGF loss through
Table 2
Multivariate Analysis of Six-Month Survival
Variable BMT CTN 0302 BMT CTN 0802
HR 95% CI P Value HR 95% CI P Value
Age > 40 yr 3.9 1.1-17.7 .03 3.3 1.1-14.6 .03
Grade .17 .07
1 1.0 - 1.0 -
2 2.0 .34-39.0 .7 .2-2.7
3 5.1 .85-100.8 2.0 .5-8.7
4 2.8  108 0-132.6 1.8  109 0-2.2
Day 28 response .01 .001
CR 1.0 - 1.0 -
PR .7 .2-2.6 1.7 .4-6.1
NR 3.7 1.2-11.4 5.0 2.0-13.7
Day 28 FS  2000 pg/mL 9.3 1.3-59.1 .002 2.8 1.04-6.9 .04
Onset Ang2  8000 pg/mL 3.0 .6-11.7 .05 .3 .03-1.2 .09
Day 28 Ang2  8000 pg/mL .6 .05-5.1 .14 5.2 1.7-13.9 .006
Day 28 sEng  3000 pg/mL .9 .04-8.5 .60 1.1 .5-2.6 .70
Day 28 PlGF  20 pg/mL 4.7 1.4-21.7 .005 1.8 .6-6.7 .30
HR indicates hazard ratio; CI, conﬁdence interval.
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possible.
Our initial pilot data were validated in 2 separate cohorts
of patients from multicenter GVHD trials, lending external
validity to the results. We also analyzed both serum and
plasma in the different cohorts and were able to conﬁrm that
plasma is the preferred sample type for measuring EGF and
VEGF-A.We note that only a few patients had severe grade III
and IV aGVHD in the BMT CTN trials, and this may have
compromised our ability to observe differences in these an-
alyses with varying aGVHD severity. These validated ﬁndings
associating AF, aGVHD response, and survival can be further
hypothesis generating for future studies into the patho-
physiology and therapy of aGVHD.
Levels of EGF and VEGF-A were signiﬁcantly lower and
more closely associated with response in CTN 0802, where
plasma, as opposed to serum, was analyzed. Serum has
higher levels of EGF and VEGF-A relative to plasma because
of release from activated platelets [28,29]. Some of the dif-
ferences we observed regarding AF and outcomes in the 2
trials may reﬂect the different sample sources, and further
studies of these factors should ideally use plasma samples.
Nonetheless, EGF serum levels were still signiﬁcantly lower
in aGVHD in CTN 0302 compared with the levels in recipient
controls, which were 2 to 3 times the reported normal serum
levels [22,23]. It is possible that increased EGF production
beyond the normal basal state accompanies post-HCT re-
covery, but this requires further study.Figure 5. Two-year survival by follistatIn addition to the relative deﬁciency of circulating trophic
growth factors for healing in aGVHD (EGF and VEGF-A), we
also identiﬁed markers of endothelial damage after alloge-
neic HCT that were further dysregulated in aGVHD (FS and
PlGF). Increased levels of circulating PlGF may reﬂect an
underlying enhanced inﬂammatory state with higher levels
of TNFa (rank correlation, .58; P ¼ .001, unpublished), and
increasing levels of FS may reﬂect greater endothelial dam-
age and/or neovascularization. The results of this study
contribute to the ﬁndings of endothelial-derived factors that
are abnormal in aGVHD [34,35]. Interestingly, despite
widespread inﬂammation and endothelial activation/injury,
thrombosis is infrequent in severe aGVHD [36].
We observed that FS levels are signiﬁcantly elevated after
allogeneic HCT and are even higher after onset of aGVHD in
both serum and plasma. The tissue source of excess FS in
aGVHD is unknown. FS was ﬁrst identiﬁed for its follicle-
stimulating hormone inhibitory activity in ovarian follicular
ﬂuid [37], although it has more recently been shown to play a
role in angiogenesis and function as a speciﬁc binding protein
(and neutralizer) of activin-A, a ubiquitously expressed pro-
tein with proinﬂammatory and proﬁbrotic properties that is
elevated after allogeneic HCT [15,38,39]. However, FS is also a
key regulator of tissue regeneration after injury [40]. Sup-
plemental FS was recently shown to reduce mortality in ro-
dent models of gram-negative sepsis [41] and IBD [42], and FS
overexpression was associated with improved muscle healing
after laceration [43]. We recently identiﬁed that circulating FSin (FS) level at day 28 of aGVHD.
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male fetus as opposed to those carrying a female fetus [44],
suggesting that elevated FSmay reﬂect adaptation to a greater
immunologic challenge for the mother. Its association with
poor outcomes in both GVHD trials suggest that marked ele-
vations in FS may reﬂect endothelial damage [45,46], an
established manifestation of steroid-refractory aGVHD [19],
and/or neovascuarlization [43], which is associated with
worsened aGVHD in rodents [5,6].
In summary, we observed that EGF and VEGF-A, factors
involved in repair and regeneration, are low in aGVHD pa-
tients compared with levels in controls. EGF and VEGF-A are
also associated with response to therapy, best recognized in
plasma samples. AFs indicative of damage and inﬂammation,
FS and PlGF, were elevated at the onset of aGVHD in both
serum and plasma. Elevated FS at day 28 after initial aGVHD is
associated with poor 6-month survival in both CTN 0302 and
0802. Ang2 and sEng decrease over time after effective aGVHD
therapy. Finally, PlGF levels are disproportionately elevated in
aGVHD after unrelated donor HCT but are also associated with
overall survival in patients without aGVHD. Mechanistic
studies are needed to clarify the role of these factors in post-
HCT recovery, yet these data support the critical impact of the
host healing capacity aswell as endothelial damage for clinical
response and survival after aGVHD.ACKNOWLEDGMENTS
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